Summary

A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:

• RYBREVANT^® (amivantamab-vmjw) – CHRYSALIS Study
  • Minimum requirement to access interactive content: Adobe Acrobat Reader
• An overview of the CHRYSALIS Cohort D study design and results is available in video format: VIDEO LINK.
• The executive summary infographic of the iPDF content is provided below.